Vaxart prices $15M public offering of 16M shares; net ~$13.6M

Vaxart, Inc.

Offering of 16M shares of common stock at $0.9375 per share for gross proceeds of $15M.
Net proceeds expected ~$13.6M (or ~$15.7M if underwriter's 30-day option fully exercised).
Underwriter Cantor Fitzgerald granted a 30-day option to purchase up to 2.4M additional shares.
Proceeds to be used for clinical/preclinical development, manufacturing, and general corporate purposes.
Offering expected to close June 9, 2023, subject to customary conditions.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vaxart, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. (effective 2023-06-07).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co.
Effective: 2023-06-07

Exact text from the filing

On June 7, 2023, Vaxart, Inc. (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to issue and sell to Cantor 16,000,000 shares of the Company’s common stock, par value $0.0001 (the “Common Shares”) in an underwritten public offering (the “Offering”), pursuant to a Registration Statement on Form S-3 (File No. 333-270671) and the related prospectus and prospectus supplement, in each case filed with the U.S. Securities and Exchange Commission (the “SEC”).

View on SEC.gov

Browse all material agreements →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-016984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.